Back/Castle Biosciences CFO Frank Stokes Honored with 2026 Houston Business Journal Award
pharma·June 24, 2026·cstl

Castle Biosciences CFO Frank Stokes Honored with 2026 Houston Business Journal Award

ED
Editorial
Cashu Markets·2 min read
Castle Biosciences CFO Frank Stokes Honored with 2026 Houston Business Journal Award
TL;DR
  • Castle Biosciences celebrates CFO Frank Stokes receiving the 2026 CFO Award for his exceptional financial leadership.
  • Under Stokes' guidance, Castle Biosciences achieved significant successes, including a Nasdaq IPO and strategic acquisitions.
  • The company focuses on enhancing patient care through innovative testing solutions in dermatologic and gastroenterological disorders.

Castle Biosciences, Inc. (CSTL), a leading diagnostics company focused on innovative health solutions, celebrates the recognition of its Chief Financial Officer, Frank Stokes, as a recipient of the 2026 CFO Awards by the Houston Business Journal. This achievement highlights Stokes' exceptional leadership within the realm of finance and his contributions to the company's trajectory. The awards event, scheduled for July 30, will honor Stokes along with 21 other CFOs from the Greater Houston area, with a feature in the July 31 issue of the Houston Business Journal. Since Stokes took the helm as CFO in December 2017, he has been integral to many of Castle Biosciences' successes, which include a notable initial public offering on Nasdaq in 2019 and several strategic acquisitions that have solidified the firm's market presence.

Visionary Leadership in Financial Management

Stokes' leadership is characterized by financial discipline and a forward-thinking approach, which have significantly influenced Castle Biosciences' operations. The firm is dedicated to enhancing patient care through personalized testing solutions, particularly in dermatologic and gastroenterological disorders. Under his guidance, the company has not only expanded its product offerings but also committed to empowering both patients and clinicians with advanced molecular testing capabilities. Derek Maetzold, CEO of Castle Biosciences, commends Stokes for his vision and discipline, attributes that contribute greatly to Castle's ongoing growth and innovation.

In response to his recognition, Stokes reflects on the collaborative spirit of the Castle team, emphasizing the importance of collective effort in advancing healthcare through rigorous science. His pride in working alongside a talented group underscores the company's dedication to providing superior patient care through innovative solutions. Castle Biosciences continues to reinforce its belief in empowering health through science, solidifying its position as a key player in the diagnostics industry while enhancing treatment planning for patients.

Celebrating Financial Excellence

Stokes' acknowledgment as a distinguished CFO showcases the strong financial leadership that propels Castle Biosciences toward its mission. As the company looks to the future, it remains committed to not only recognizing individual accomplishments but also fostering an environment conducive to continuous improvement in patient care amid an evolving healthcare landscape.